Abstract: A SHP2 phosphatase allosteric inhibitor and a drug containing said inhibitor, the SHP2 phosphatase allosteric inhibitor having the structure shown in formula (I), and the use of an optical isomer compound of the SHP2 phosphatase allosteric inhibitor or a pharmaceutically acceptable salt thereof in the preparation of drugs for the treatment of tumor diseases.

Abstract: Disclosed are a method and an apparatus for optimizing and testing a harness layout of a battery swapping electrical interface. The method includes: obtaining a first distance, a second distance and initial floating data of the battery swapping electrical interface; adjusting the first distance and the second distance to obtain first floating data of the battery swapping electrical interface again; repeatedly inserting or pulling the plug into or out of the socket of the battery swapping electrical interface; obtaining second floating data of the battery swapping electrical interface after repeatedly inserting or pulling the plug into or out of the socket for a preset number of times; and determining the current first distance and second distance as optimal distances if it is judged that the second floating data is in the second index interval.

Abstract: The application relates to an anti-back-transfer intake structure of a rotating detonation combustion chamber including a Tesla valve communicating with the rotating detonation combustion chamber and arranged at an inlet of the rotating detonation combustion chamber. The Tesla valve includes a casing and a flow passage, the casing is coaxially connected with an outer wall of the rotating detonation combustion chamber, the flow passage is arranged in the casing, and the flow passage has an inlet end for introducing air, and an outlet end connected with an annular passage of the rotating detonation combustion chamber.

Abstract: The present disclosure relates to a medical device. The medical device comprises a matrix and a first coating coated on the matrix. The matrix contains a metal element X having a content of ?5 wt %; the first coating is at least one of an elemental metal layer of the metal element X, an alloy layer of the metal element X, and a metal-ceramic layer of the metal element X; and the first coating does not contain nickel and cobalt. The medical device has good use safety, reliability, and biocompatibility, so that a product can meet a use requirement of large plastic deformation, and has good reliability during use. The medical device can particularly meet requirements of product with large plastic deformation during use, such as medical implant devices.

Abstract: The application relates to an anti-back-transfer intake structure of a rotating detonation combustion chamber including a Tesla valve communicating with the rotating detonation combustion chamber and arranged at an inlet of the rotating detonation combustion chamber. The Tesla valve includes a casing and a flow passage, the casing is coaxially connected with an outer wall of the rotating detonation combustion chamber, the flow passage is arranged in the casing, and the flow passage has an inlet end for introducing air, and an outlet end connected with an annular passage of the rotating detonation combustion chamber.

Abstract: Provided are an implantable medical device (100) and a method for manufacturing the same, and a method for manufacturing a stent. The implantable medical device (100) comprises a metal base (110) and a cladding layer (120). The cladding layer (120) is a nickel-free and cobalt-free metal layer which is deposited on the metal base (110) by means of a metal bond. The arrangement of the cladding layer (120) of the implantable medical device (100) on the metal substrate (110) can prevent carcinogenic elements in the metal base (110) such as nickel and cobalt from dissolution. Moreover, the cladding layer (120) is a nickel-free and cobalt-free metal layer, such that the implantable medical device (100) is free from problems of nickel or cobalt dissolution, thereby improving the biological safety of the implantable medical device (100).

Abstract: A SHP2 phosphatase allosteric inhibitor and a drug containing said inhibitor, the SHP2 phosphatase allosteric inhibitor having the structure shown in formula (I), and the use of an optical isomer compound of the SHP2 phosphatase allosteric inhibitor or a pharmaceutically acceptable salt thereof in the preparation of drugs for the treatment of tumor diseases.

Abstract: A method may include: generating, by a controller, a first user interface configured to control selection of a first attribute from a set of attributes; generating, by the controller, a second user interface generated based on the controlled selection of the first attribute, the second user interface configured to enable selection of values with respect to the first attribute; generating, by the controller, a first query to enable querying at the database based on the one or more values with respect to the first attribute; generating, by the controller, a second query for execution at the database, when the first query fails to respond with a match, the second query including a first vector representative of a profile to enable querying the database; and generating, in response to the first query and/or the second query, a third user interface indicative of a result.